Prima BioMed Gains Belgian Regulatory Approval to Commence

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Prima BioMed Gains Belgian Regulatory Approval to Commence a Registration Phase IIb Study of IMP321

SYDNEY, AUSTRALIA--(Marketwired - Oct 27, 2015) - Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD )

  • Belgium's Federal Agency for Medicines and Health Products Approved the Commencement of the AIPAC Study
  • IMP321 Phase IIb trial initiation is expected before the end of 2015

Prima BioMed Ltd ( ASX : PRR ) ( NASDAQ : PBMD ), a leading immuno-oncology company, is pleased to announce its first regulatory approval facilitating commencement of the landmark Phase IIb clinical study of IMP321, Prima's lead compound.

The AIPAC ( A ctive I mmunotherapy PAC litaxel) clinical trial application has been cleared by Belgium's Federal Agency for Medicines and Health Products (FAMHP). AIPAC is a multi-national, randomized, double-blind, placebo-controlled Phase IIb study of IMP321 in metastatic breast cancer, which has received Scientific Advice from the European Medicines Agency (EMA). Prima continues work to obtain ethics approval by the Institutional Review Boards (IRB) at the chosen study sites in Belgium. IRB approval is the final approval required before trial initiation.

Prima's CSO & CMO, Dr. Frédéric Triebel, said, "Prima BioMed has, over the last 10 months, assembled a first class team to work on AIPAC. The clearing of our study protocol by FAMHP represents a big step forward for the team and we are on track to commence the study by the end of 2015."

AIPAC - A key study

IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.

IMP321 has been shown in an open-label Phase I study 1 to be able to double the expected six-month response rate in HER-2 negative metastatic breast cancer patients receiving standard-of-care paclitaxel, from a 25% historic response rate 2 (RECIST criteria) to 50% when combined with IMP321. AIPAC has been designed to confirm this expected response and evaluate its effect on patient survival in a randomized, double blind, placebo-controlled setting and in a comparable patient population. Progression-Free Survival (PFS) will be AIPAC's primary endpoint. RECIST response rates and Overall Survival are among the secondary endpoints. The design of the study has been examined by the EMA's Scientific Advice expert panel in the view of using these data for Marketing Authorization in the EU in tested setting.

The protocol that arose from Prima's interaction with the EMA will see women recruited into AIPAC with metastatic breast cancer where the tumour is HER-2-negative but hormone receptor positive. These patients will be receiving paclitaxel as first line chemotherapy after having failed on hormone therapy. They will represent a large patient population (hormone receptor-positive breast cancer is accounting for app. 75 percent of all cases) for which there are few viable treatment options, as indicated by the fact that PFS in such patients can be as low as six months 3 . 

In the AIPAC study, patients will be administered subcutaneous doses of IMP321 on days 2 and 16 of a weekly regimen of paclitaxel, the day after their paclitaxel infusion.

AIPAC will aim to initially recruit 15 patients for a smaller safety run-in in three different countries. This section of the trial will test in combination with paclitaxel the safety of IMP321 in doses up to 30 mg per dose, which has previously been shown to be safe when tested as a monotherapy 4 and is significantly higher than the maximum 6.25 mg dose from the Phase I in metastatic breast cancer. This section of AIPAC, extending into 2016, and will yield valuable safety, pharmacokinetic and pharmacodynamic data that Prima expects to report in the second half of 2016.

After the safety run-in, the AIPAC investigators will proceed to recruit 196 patients, randomising them 1:1 to either standard-of-care paclitaxel plus placebo or paclitaxel plus IMP321 for six months as per the Phase I dosing regimen, after which the responding or stable patients will be maintained for another year with monthly IMP321 injections. The study has been powered to show a four-month PFS advantage for the treatment group. Allowing time for patient recruitment and follow-up, AIPAC's expected duration is around three years. Throughout the study, an independent data monitoring committee will review patient safety, survival rates and demographics at regular intervals. No interim statistical analysis is planned.

Prima envisages setting up at least 30 study sites for AIPAC in six European countries -- starting with Belgium, France and the Netherlands. While Belgian regulatory approval has now been received for AIPAC, the relevant approvals are still to be obtained for the other countries.

About Prima BioMed

Prima BioMed is a globally active biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses for cancer chemo-immunotherapy and in other combinations which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Prima BioMed is listed on the Australian Stock Exchange, and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au .

1 See Brignone et.al., J. Transl. Med. 2010, 8:71. 2 Miller et. al., N. Engl. J. Med. 2007, 357: 2666-76. 3 Miller et. al., op. cit. 4 See Brignone et.al. Clin. Cancer Res. 2009, 15:6225-31.

For further information please contact: Prima BioMed Ltd: Stuart Roberts +61 (0) 447 247 909 stuart.roberts@primabiomed.com.au Australia Investor/Media: Mr Matthew Gregorowski Citadel Communications +61 (0) 422 534 755 mgregorowski@citadelpr.com.au

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 308

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 23

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 225

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 246

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 232

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 377

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 156

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Zixi Unveils Advanced Video Solutions for Live Sports in 2025

Updated Category News Views 319

Zixi's Innovative Showcase at IBC 2025 IBC stand 5.A85 Zixi, the Emmy Award-winning leader in broadcast-quality live video over IP, is set to exhibit at IBC 2025 held in Amsterdam. At Stand 5.A85, the company will reveal groundbreaking innovations aimed at enhancing the live video experience for broadcasters, sports leagues, service providers, and OTT platforms. With a...

Continue Reading
Discover the Incredible Growth of Agnico Eagle Mines Over 20 Years

Updated Category News Views 165

Discovering the Long-Term Success of Agnico Eagle Mines Agnico Eagle Mines (NYSE: AEM) has demonstrated impressive performance in the stock market over the last 20 years. With a remarkable average annual return of 9.52%, the company has outperformed the market by 1.17% each year. Currently, Agnico Eagle holds a market valuation of $41.72 billion, showcasing its strong...

Continue Reading
Join the Race for Excellence in Bartending Skills Today

Updated Category News Views 276

USBG Presents World Class Sponsored By DIAGEO Launches Bartender Competition The esteemed bartending competition is now open for applications, inviting skilled mixologists to step into the limelight for a chance to become the 2025 U.S. Bartender of the Year. With application deadlines coming up quickly, anyone with the passion, creativity, and skill should take advantage...

Continue Reading
Sunflower Therapeutics Secures $3 Million SAFE for Future Growth

Updated Category News Views 370

Sunflower Therapeutics Secures Oversubscription of $3 Million SAFE Sunflower Therapeutics, a public benefit corporation dedicated to improving global protein manufacturing, recently announced the successful oversubscription of a $3 million Simple Agreement for Future Equity (SAFE). This achievement illustrates strong investor confidence in the company's mission to enhance...

Continue Reading
Future Growth of Video Surveillance Market Projected to Soar

Updated Category News Views 42

Forecast for Video Surveillance Market Growth The video surveillance market is witnessing remarkable expansion, with a projected value of USD 54.42 billion by the year 2024 and an impressive rise to USD 88.71 billion anticipated by 2030. This growth represents a compounded annual growth rate (CAGR) of 8.5% during the upcoming forecast period. Various factors contribute to...

Continue Reading